Victoria Vakiener Biography and Net Worth

Victoria Vakiener served as Chief Commercial Officer of Epizyme, Inc. (2018-2021), a biopharmaceutical company that was acquired in 2022, where she built the commercial organization and launched TAZVERIK for two indications within six months.  Prior to joining Epizyme, Ms. Vakiener was an executive at Johnson & Johnson (NYSE: JNJ) for more than twenty years, where she held positions of leadership with increasing responsibility across the company’s pharmaceutical and diagnostics businesses. She started her pharmaceutical career at Schering-Plough, where she spent nine years in both scientific and commercial roles. 

Ms. Vakiener currently serves on the board of Chimerix (NASDAQ: CMRX), a clinical-stage biopharmaceutical company.

Victoria Vakiener holds a BS in Biochemistry from Albright College.

What is Victoria Vakiener's net worth?

The estimated net worth of Victoria Vakiener is at least $400,216.25 as of May 2nd, 2024. Vakiener owns 30,205 shares of Arrowhead Pharmaceuticals stock worth more than $400,216 as of April 27th. This net worth approximation does not reflect any other investments that Vakiener may own. Learn More about Victoria Vakiener's net worth.

How do I contact Victoria Vakiener?

The corporate mailing address for Vakiener and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at ir@arrowheadpharma.com. Learn More on Victoria Vakiener's contact information.

Has Victoria Vakiener been buying or selling shares of Arrowhead Pharmaceuticals?

Victoria Vakiener has not been actively trading shares of Arrowhead Pharmaceuticals during the last ninety days. Most recently, Victoria Vakiener sold 1,799 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a transaction totalling $41,934.69. Following the completion of the sale, the director now directly owns 30,205 shares of the company's stock, valued at $704,078.55. Learn More on Victoria Vakiener's trading history.

Who are Arrowhead Pharmaceuticals' active insiders?

Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Hongbo Lu (Director), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), Victoria Vakiener (Director), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Arrowhead Pharmaceuticals?

In the last year, insiders at the biotechnology company sold shares 15 times. They sold a total of 434,505 shares worth more than $7,271,437.48. The most recent insider tranaction occured on April, 11th when CEO Christopher Richard Anzalone sold 50,800 shares worth more than $583,692.00. Insiders at Arrowhead Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.

Information on this page was last updated on 4/11/2025.